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S358 Poster Session IIThese findings suggest that the reduced GvHD was not due to re-
duced function, altered subsets or relative deficiency of allogeneic
donor T cells but from an alteration of in vivo trafficking of
IFNgR-/- T cells compared to WT T cells. We further demon-
strated that the IFNgR-mediated signaling in alloreactive donor T
cells was required for expression of CXCR3 which has been impli-
cated in trafficking of T cells to areas of inflammation and target or-
gans, commonly known to be the sites of GvHD. In addition,
overexpression of CXCR3 in IFNgR-/- T cells rescued the
GvHD-inducing function of IFNgR-/- T cells. CXCR3-/- T cells
and pharmacological approaches using inhibitors of IFNgR signal-
ing recapitulated the anti-GvHD (and pro-GvL) effects seen in
IFNgR-/- T cells after allo-HSCT. Thus, the IFNgR-CXCR3
axis represents a promising therapeutic target for future efforts to
mitigate GvHD while maintaining GvL after allo-HSCT.
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ULTRA LOW-DOSE IL-2 MEDIATED EXPANSION OF REGULATORY T
CELLS AS GVHD PROPHYLAXIS FOR RECIPIENTS OF ALLOGENEIC HEMA-
TOPOIETIC STEM CELLS
Kennedy-Nasser, A.A.1, Ku, S.1, Melenhorst, J.2, Barrett, J.2,
Hazrat, Y.1, Durett, A.G.1, Foster, A.1, Savoldo, B.1, Yvon, E.1,
Heslop, H.E.1, Carrum, G.1, Kamble, R.T.1, Brenner, M.K.1,
Krance, R.A.1, Bollard, C.M.1 1Baylor College of Medicine, Houston,
TX; 2National Institutes of Health, Bethesda, MD
CD4+ CD25+ FoxP3+ regulatory T cells (Tregs) may prevent graft-
versus-host disease (GvHD) after allogeneic hematopoietic stem cell
transplantation (HSCT). We and others have previously used low-
dose IL-2 therapy in HSCT recipients in an attempt to enhance an-
titumor immunity and observed low rates of GvHD. Retrospective
analysis showed that patients who received IL-2 had higher levels
of FoxP3+ T cells than controls, suggesting that IL-2 may preferen-
tially expand Tregs in vivo, thereby preventing GvHD.We therefore
initiated a prospective phase II clinical trial to evaluate the efficacy
and toxicity of ultra low-dose (ULD) IL-2 injections following allo-
geneic HSCT to promote Treg expansion in vivo and prevent signif-
icant GvHD. As our control population, we evaluated Treg
reconstitution post HSCT in patients who did not receive IL-2.
Twelve patients have been treated with ULD IL-2 (100,000 to
200,000 IU/m2 3x weekly SC) post HSCT starting before day 30
and continuing for 6 to 12 weeks. Median age at time of HSCT
was 14 years (range, 6y to 56y). Eight patients received matched sib-
ling donor transplants and four received alternative donor trans-
plants with Campath 1-H for in vivo T-cell depletion. By flow
cytometry, all patients demonstrated a rise in the percentage of
CD4+ CD25+ FoxP3+ Tregs by 6 weeks following initiation of IL-2
therapy with a mean of 5.2% (range, 0 to 11.0%) pre IL-2 to
a mean of 13.2% (range, 4.4 to 31.1%) post treatment. Compared
to the control HSCT population, a significant rise in Treg percent-
ages was found at 1 and 3 months post HSCT in patients receiving
IL-2 (1 month: 12.8% vs. 6.8%, p 5 0.008; 3 months: 10.5% vs.
6.2%, p5 0.02). Functional analyses of CD4+ CD25bright cells dem-
onstrated suppression ofmixed lymphocyte reactions. There were no
grade 3 or 4 toxicities associated with ULD IL-2. No patients on
study developed grade III-IV acute GvHD, compared to 4/31
(13%) of controls. IL-2 recipients also retained T cells reactive to vi-
ral and tumor antigens, and only 25%of study patients versus 61%of
the control group developed viral infections. Hence, ULD IL-2 is
well-tolerated, expands a CD4+ CD25+ FoxP3+ Treg population in
vivo, andmay be associated with a lower incidence ofGvHDand viral
infections; the study continues to evaluate these putative benefits.417
INTERLEUKIN-15 (IL-15) ADMINISTRATION INCREASES GRAFT VERSUS
LEUKEMIA ACTIVITY IN RECIPIENTS OF HAPLOIDENTICAL HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Sauter, C., Bailey, C., Biswas, C., Budak, T., Panis, M., Alpdogan, O.
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
The success of haploidentical (HI) hematopoietic stem cell trans-
plantation (HSCT), suggests that graft-versus leukemia (GVL) ef-
fect might have a substantial role in this transplant modality.Rigorous T-cell depletion (TCD) of the graft decreases the occur-
rence of graft-versus-host disease (GVHD) in HI-HSCT, however
this results in immunodeficiency and high disease relapse rate, espe-
cially in patients with resistant or residual leukemia. Therefore, en-
hancingGVL activity of HSCTwithout increasingGVHD is crucial
for improving the outcome of haploidentical transplant.
Post-transplant IL-15 administration is shown to enhance im-
mune reconstitution, particularly donor-derived NK and CD8+ T
cell populations in murine models. We evaluated the efficacy of
IL-15 for enhancing GVL effect in recipients of HI-HSCT. For de-
veloping clinically relevant haploidentical transplant models, differ-
ent hybrid mice with B6 background that share the same haplotype
(H2Kb) are used for our murine haploindentical transplant experi-
ments. Lethally irradiated B6D2F1/J (H2Kb/d) mice are trans-
planted with B6CBAF1/J (H2Kb/k) TCD bone marrow (BM) and
T cells at varying doses. Some animals were also given P815 tumor
cells on the day of transplant. Administration of IL-15 significantly
increased the numbers of CD8+ T and NK cells in the spleen and
BM in the T cell depleted model at post-transplant day 28. Infusion
of very low dose haploidentical T cells (1x104) with TCD-BM re-
sulted in a conflicting effect on immune reconstitution, i.e. increased
T cell numbers, and decreased NK cell population. Post-transplant
IL-15 administration also changed this immune reconstitution pat-
tern and significantly increased both T and NK cell numbers in re-
cipients of HI-HSCT. In P815 challenged mice that were
transplanted with very low dose T cell added TCD-BM, IL-15 ad-
ministration significantly increased anti-tumor activity of the graft
and improved survival without increasing GVHD. This effect was
observed when IL-15 administration was given at a later time point
rather than immediately following transplantation, possibly allowing
for more donor cell engraftment and T cell proliferation to take
place. IL-15 administration without T cell infusion did not result
in any survival improvement. We conclude that in our experimental
HI transplant models, IL-15 administration augments anti-tumor
activity of the HI-HSCT without increasing GVHD risk, and this
effect requires presence of donor derived T cells.418
COMPARISON OF MYCOPHENOLATE MOFETIL (MMF) VERSUS METHO-
TREXATE (MTX) FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DIS-
EASE: RESULTS OF A META-ANALYSIS
Kharfan-Dabaja, M.A.1, Mhaskar, R.2, Pidala, J.A.3, Perkins, J.B.3,
Djulbegovic, B.2, Kumar, A.2 1American University of Beirut, Beirut,
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Background: morbidity and mortality resulting from acute and
chronicGVHD remains themost serious challenge to wider applica-
bility of T-cell replete allogeneic HCT for otherwise incurable he-
matologic diseases. Developing effective regimens acute GVHD
(aGVHD) prophylaxis is of vital importance due to lack of effective
treatments, mainly when refractory to corticosteroids. Conflicting re-
sults have been observed when comparing, directly or indirectly,
MMF-based against MTX-based regimens for aGVHD prophylaxis.
Methods: a systematic and comprehensive literature search was per-
formed using MEDLINE databases from 1966 to 07/31/2011. All
completed prospective-randomized (phase II or III) clinical trials
(RCT) or retrospective non-randomized comparisons (NRC) pub-
lished as a full manuscript were eligible for inclusion, but data pub-
lished only in abstract form was not. Outcomes extracted from
selected studies (RCT 5 2, retrospective NRC 5 2) included:
time-to-ANC engraftment, time-to-platelets engraftment, inci-
dences of grade II-IV aGVHD and chronic GVHD (cGVHD), inci-
dence of severe mucositis, frequency of pain control requirement,
frequency of total parenteral nutrition (TPN) use, relapse rate, inci-
dence of non-relapse mortality (NRM) and overall survival (OS).
Results: pooled analysis shows that use of MMF, for aGVHD pro-
phylaxis, results in significantly faster platelets engraftment (pooled
hazard ratio (HR)5 1.15 (95%CI, 1.08,1.23; p\0.0001)), a lower in-
cidence of severe mucositis (pooled risk ratio (RR) 5 0.48 (95%CI,
0.32, 0.71; p 5 0.0003)), and less use of TPN (pooled RR 5 0.52
(95%CI, 0.34, 0.80; p5 0.003)) or narcotics for pain control (pooled
risk ratio5 0.76 (95%CI, 0.63, 0.91; p5 0.002)) compared toMTX.
